ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,313.00
0.33%
Gold vs US Dollar
2,652.97
-0.73%
Brent Oil
71.97
1.44%
Bitcoin
65,824.31
0.98%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) News

Fate Therapeutics (FATE)

Fate Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FATE
DateTimeSourceHeadlineSymbolCompany
12/09/202421:01GlobeNewswire Inc.Fate Therapeutics to Present at 2024 Cantor Global Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
30/08/202421:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
21/08/202421:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
13/08/202421:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FATEFate Therapeutics Inc
13/08/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
13/08/202421:05GlobeNewswire Inc.Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
07/08/202421:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
02/08/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
31/07/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
31/07/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
31/07/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
31/07/202422:59Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
31/07/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
31/07/202413:00GlobeNewswire Inc.Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of DirectorsNASDAQ:FATEFate Therapeutics Inc
02/07/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
11/06/202423:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
11/06/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
11/06/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
11/06/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
10/06/202422:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FATEFate Therapeutics Inc
10/06/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
07/06/202422:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
04/06/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
31/05/202422:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
29/05/202421:01GlobeNewswire Inc.Fate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
09/05/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202421:01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202413:30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202413:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Your Recent History

LSE
VAST
Vast Resources
LSE
SOLG
Solgold
LSE
PANR
Pantheon Resources
LSE
NEO
Neo Energy Metals
LSE
SYME
Supply@me Capital
LSE
HUM
Hummingbird Resources
LSE
OPTI
Optibiotix Health
LSE
GEX
Georgina Energy
LSE
ZPHR
Zephyr Energy
LSE
SCLP
Scancell
LSE
API
Abrdn Property Income
LSE
SBTX
Skinbiotherapeutics
LSE
IES
Invinity Energy Systems
LSE
QBT
Quantum Blockchain Techn...
LSE
POS
Plexus
LSE
UPS
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved